Top Stories
L&T Partners with PS Technology to Revolutionise Railways
6 mins read. August 2, 2024 at 12:45 PM
Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr
4 mins read. August 2, 2024 at 12:41 PM
Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr
4 mins read. August 2, 2024 at 12:36 PM

Dr. Reddy's Laboratories faces legal action in the United States
Dr. Reddy's Laboratories, Inc., a wholly-owned step-down subsidiary of Dr. Reddy's Laboratories Limited, has found itself among several pharmaceutical companies named as defendants in a complaint filed on October 6, 2023. The complaint was lodged in the United States District Court for the Northern District of California by Mayo Clinic and Lifepoint Corporate Services.
The complaint alleges violations of federal and state antitrust laws, as well as other state laws, asserting that the defendants engaged in improper competition restraint and maintained a shared monopoly in the sale of brand and generic Revlimid through settlements of patent litigation. According to the complaint, these agreements resulted in an improper delay of generic entry until 2022 and then limited generic competition through 2026.
In response to these allegations, Dr. Reddy's Laboratories has stated that it believes the claims lack merit and has vowed to vigorously defend itself against the litigation.
Related News

L&T Partners with PS Technology to Revolutionise Railways
6 mins read. August 2, 2024 at 12:45 PM

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr
4 mins read. August 2, 2024 at 12:41 PM

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr
4 mins read. August 2, 2024 at 12:36 PM

NBCC Arm Gets Two Construction Projects Worth Rs 443.61 Cr
4 mins read. August 2, 2024 at 12:33 PM
Download app
Access BlinkX
everywhere
across device
